How to handle hearsay
Bill Lackey has been fielding calls - lots of them - from fund managers wondering if Computer Sciences Corporation (CRC) is planning to sell its profitable Australian division. Michael Becker keeps hearing from shareholders that one of biotech developer Cytogen's medical patents is having trouble in its trials. And Janet Point is routinely updated by investors on the status of InterDigital Communication's seven year-old patent infringement lawsuit against Swedish competitor Ericsson. 'No comment,'
You need to register to access 3 free deep dive articles per month. To continue reading please register or login below..
- Unlimited deep dives
- Data-driven research around key topics
- Buy-side insights
- Benchmarking reports
From
$1495
Betsy Pisik
Award winning journalist, staff and freelance writer, ghost writer, speech writer, researcher
